BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15544933)

  • 1. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.
    Komm BS; Vlasseros F; Samadfam R; Chouinard L; Smith SY
    Bone; 2011 Sep; 49(3):376-86. PubMed ID: 21658483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats.
    El-Shitany NA; Hegazy S; El-Desoky K
    Phytomedicine; 2010 Feb; 17(2):116-25. PubMed ID: 19577454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
    Kangas L; Härkönen P; Väänänen K; Peng Z
    Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
    Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
    Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
    Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
    Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
    Ke HZ; Crawford DT; Qi H; Pirie CM; Simmons HA; Chidsey-Frink KL; Chen HK; Jee WS; Thompson DD
    Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V; Birchman R; Wu DD; Lindsay R
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    Clin Cancer Res; 2004 Sep; 10(17):5717-23. PubMed ID: 15355898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
    Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
    Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.